INTRODUCTION
Mature B cells are stringently selected for the continuous expression of a functional B-cell receptor (BCR) throughout their life, and loss of BCR expression leads to rapid cell death [1, 2] . The majority of B-cell malignancies remain dependent on functional BCR, whereas others lack BCR expression, either because of their maturation state or because of selection pressure against the expression of a functional BCR (Table 1) [3] [4] [5] [6] [7] [8] [9] [10] . Although the BCR is thought to contribute to malignant transformation in most BCR-expressing malignancies, it may serve as a tumor suppressor in BCR-negative B-cell malignancies [11] [12] [13] . Developing B cells can be classified into different stages according to the expression of differential surface markers (Hardy Fraction A-F) [14] . In Fraction C 0 , the pre-BCR is expressed after successful rearrangement of the m heavy chain and pairing with the surrogate light chain (VPREB and l5). The expression causes selfaggregation and results in clonal proliferation and downregulation of pre-BCR components [15] . After further maturation and rearrangement of the light chain, the surrogate light chains of the pre-BCR are replaced by k or l light chains, which together with the m heavy chain form the BCR on mature B cells. and the BCR exhibit ligand-independent 'tonic' signaling, mature B cells are typically activated by the engagement of the BCR by antigen, for instance in germinal centers. Despite their structural similarities, the outcome of pre-BCR and BCR signaling can be divergent and may depend on the expression levels and cellular organization of signaling components, expression of downstream mediators (i.e. transcription factors), and the chromatin structure [16] [17] [18] [19] .
In mature B cells, monovalent antigens fail to activate the BCR. Therefore, activation was assumed to rely on cross-linking of BCRs in order to create clusters [7] . However, recent evidence indicates that in the absence of stimuli BCRs are clustered in an autoinhibitory conformation, and antigen binding disperses these clusters [20, 21] . Consequently, Rous sarcoma oncogene (SRC) kinases Lyn (Yamaguchi sarcoma viral oncogene homolog), Fyn, and B lymphoid tyrosine kinase phosphorylate the now accessible immunoreceptor tyrosine-based activation motifs (ITAMs) on Iga (CD79A) and Igb (CD79B), thereby create a docking site for the spleen tyrosine kinase (SYK) [22] [23] [24] (Fig. 1) . Activated SYK then phosphorylates direct targets such as the phospholipase Cg 2 (PLCg 2 ), Bruton's tyrosine kinase (BTK), and the adaptor molecules B-cell linker protein (BLNK) and B-cell adaptor for phosphatidylinositol 3-kinase (BCAP). Together with the phosphorylated co-receptor CD19, BCAP recruits phosphatidylinositol 3-kinase (PI3K) to the plasma membrane to generate phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ). This creates a docking site for BTK that, together with SYK, activates PLCg 2 . Activated PLCg 2 hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP 2 ) to inositol triphosphate (IP 3 ) and diacylglycerol, leading to Ca 2þ influx and protein kinase C beta (PKCb) activation. PKCb phosphorylates and activates CARD11 that, together with mucosa-associated lymphoid tissue (MALT1) and B-cell CLL/lymphoma 10, activates nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NF-kB) [25] . PKCb-mediated phosphorylation of RasGRP3 promotes guanosine triphosphate acquisition of rat sarcoma small guanosine triphosphatase (RasGTPase), which activates Raf1 and subsequently the MAP kinases ERK 1/2. Finally, BCR activation results in transcription factor activation, including nuclear factor of activated T-cells, NF-kB, and myelocytomatosis oncogene homolog (Myc) [26] . Further modulation of the signaling outcome is mediated by the co-receptors of the BCR that can either dampen signaling by recruitment of inhibitory phosphatases which oppose tyrosine kinase function, that is, CD22 and PECAM1, or promote BCR downstream signaling through amplifiers of signal transduction (e.g. MEK1-ERK1/2).
KEY POINTS
Reflecting its key role in B-cell survival and selection, the majority of B-cell malignancies remain dependent on BCR function. B-cell malignancies can be divided into BCR-addicted tumors and malignancies, in which the BCR plays a tumor-suppressive role.
Mechanisms contributing to oncogenic activation of the BCR pathway include chronic stimulation by exogenous antigen, autonomous BCR signaling, as well as mutations that activate the pathway downstream of the BCR itself.
Recent clinical trials validated tyrosine kinases (SYK and BTK) and PI3K within the BCR pathway as a novel class of therapeutic targets in a number of mature B-cell malignancies. Pre-B cells within the bone marrow represent the normal counterpart of acute lymphoblastic leukemia (ALL) in the vast majority of cases ($90%) [27] . This is surprising because pre-B cells represent a very short-lived transitional subset during early B-cell development: unless rescued through survival signals from a successfully assembled pre-BCR, pre-B cells are destined to die within days [28, 29] . During normal early B-cell development, the pre-BCR has a dual function in that it first promotes survival and proliferation of large cycling pre-B cells (Fraction C 0 ) and subsequently induces differentiation into small resting (Fraction D) pre-B cells (Fig. 2) [14, 30] . To what extent these signaling processes cooperate with the different oncogenic lesions in B-cell precursors is still under investigation.
GENETIC DEFECTS IN THE PRE-B-CELL RECEPTOR PATHWAY ARE VERY COMMON IN MOST ACUTE LYMPHOBLASTIC LEUKEMIA SUBSETS: EXCEPTIONS
The high frequency of defects in the pre-BCR-related signaling molecules in ALL cells identified by us and others suggests that the pre-BCR may counteract malignant transformation. Focal deletions of EBF1, cryptic translocations, point mutations, and monoallelic deletions of PAX5 result in reduced expression of BCR-related genes such as CD19, CD79A, BLNK, and CD72. In addition, deletions of BLNK, VPREB1, and IGLL1 as well as SYK, BLNK, CD79B, IRF4, and BTLA are described [3, 31] . On the other hand, the pre-BCR also delivers critical survival and proliferation signals, and its expression is required for abnormal lymphoproliferation [32] . In addition, previous work demonstrated that the pre-BCR-related tyrosine kinase SYK is required for MYCmediated transformation of pre-B cells [33] . Our group previously demonstrated that the pre-B-cell receptor-related signaling molecule BTK plays a central role in the oncogenic signaling of leukemia cells [34] . On the basis of these findings, it is currently unclear whether pre-BCR signaling is required to enable malignant outgrowth in ALL or functions to suppress leukemogenesis. Despite the critical role of pre-BCR signaling in ALL, the clinical successes of ibrutinib (BTK) and fostamatinib/GS-9973 (SYK) in mature B-cell lymphoma could not be recapitulated in preclinical models for ALL. Whereas ALL cells from some patients are extremely sensitive to BTK and SYK inhibition, ALL cells from other patients are completely resistant to ibrutinib (BTK) and fostamatinib/GS-9973 (SYK). Kinase-independent adaptor function as described for BTK in pre-B-cells may account for this discrepancy [35] . These findings suggest that critical additional information on pathway-specific targeting of pre-BCR signaling molecules is needed to effectively use these and other agents in the treatment of B-cell lineage ALL.
THE PRE-B-CELL RECEPTOR TYROSINE KINASES SYK AND BRUTON'S TYROSINE KINASE AS THERAPEUTIC TARGETS IN B-CELL MALIGNANCIES

DASATINIB SELECTIVELY KILLS TCF3-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
Dasatinib is widely used as ABL1 kinase inhibitor in Philadelphia chromosome positive (Ph þ ) ALL and CML, but unexpectedly showed very strong activity in all transcription factor 3(TCF3)-rearranged cases of ALL (type 1 ALL). The effect of dasatinib in TCF3-rearranged ALL cells is not ABL1 dependent because other ABL1 kinase inhibitors (imatinib and nilotinib) have no effect on these ALL cells. Interestingly, TCF3-rearranged ALL cells are also sensitive to SYK (GS-9973) and BTK (ibrutinib) inhibitors, suggesting that these ALL cells are pre-BCR dependent [36] . Given that TCF3 may directly promote the expression of IgM and k light chain and reduce the expression of the negative regulator PTPN6, this signaling pathway may be of importance [37 & ]. Recent work demonstrated that in addition to its activity on BCR-ABL1 and ABL1, dasatinib is a powerful inhibitor of the pre-BCR tyrosine kinases BTK and the SRC family kinases Lyn and B lymphoid tyrosine kinase [38] . A recent study suggested that the therapeutic effect of dasatinib on TCF3-rearranged ALL is indeed owing to selective inhibition of BTK and SRC [29, 39] (Fig. 3) . These findings are potentially relevant because they suggest that understanding the pre-BCR pathway in ALL will allow identification of patients who will benefit from drugs that target pre-BCR signaling (e.g. GS-9973 and ibrutinib). In addition, the US Food and Drug Administration (FDA)-approved ABL1 kinase inhibitor dasatinib unexpectedly kills nonPh þ type 1 ALL cells that express an active pre-BCR. It will be interesting to determine which other subsets of ALL exhibit a similar dependency on pre-BCR signaling as TCF3-PBX1 ALL.
B-CELL RECEPTOR AND ITS FUNCTION IN B-CELL LYMPHOMA
The majority of mature B-cell lymphomas express a functional BCR. In Burkitt's lymphoma, BCR expression is required to provide tonic signaling [37 & ,40 & ]. Activating mutations in TCF3 or deleterious lesions of its negative regulator ID3 in Burkitt's lymphoma are associated with increased expression of the BCR, and knockdown of CD79A and SYK was shown to reduce cell survival [37 & ].
For most types of lymphoma, there is strong evidence that the BCR signaling pathway is specifically activated and contributes to pathogenesis (e.g. follicular lymphoma, chronic lymphocytic leukemia (CLL), activated B-cell-type diffuse large B-cell lymphoma (ABC-DLBCL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) [7] ). These are characterized by the usage of stereotyped, nonrandom immunoglobulin V H segments and chronic activation of the BCR pathway, and for some, ongoing somatic hypermutation during clonal evolution [7, 41] . Several different mechanisms contribute to the activation of the BCR signaling pathway in these lymphomas: chronic exogenic antigen stimulation (hepatitis C virus in splenic MZL [42] ), chronic auto-antigen stimulation (follicular lymphoma, CLL, and MALT lymphoma [43] [44] [45] [46] 48] ). Further augmentation of BCR signaling in ABC-DLBCL has been attributed to high expression levels of B-cell CLL/lymphoma 6, which increases SYK activity by repressing the expression of the phosphatase PTPROt [49] . Importantly, removing the BCR stimulus, for example by antiviral or antibacterial treatment, results in regression of the lymphoma [50, 51] , underlining the importance of BCR stimulation in lymphoma development.
SELF-RECOGNITION IN CHRONIC LYMPHOCYTIC LEUKEMIA AND OTHER LYMPHOMA ENTITIES
Recently, novel insight in the signaling from BCR in CLL has led to further understanding of the importance of this pathway in B-cell lymphomagenesis. Similar to the pre-BCR or the BCR in nonselected,
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Nilotinib Dasatinib GS-9973 Ibrutinib . A previous study using phage display libraries identified a peptide (WNWPLPPVRQFS) that was recognized -with different affinity -by the BCR of all tested CLL samples, irrespective of IGHV gene use or mutational status, but did not bind to the control samples [52] . Homologies between this epitope and a sequence within the BCR itself have led to the identification of a selfbound epitope in FR2 [47 && ]. For CLL, further studies using phage display identified alternative epitopes for autostimulatory mechanisms in CLL [53] . The finding that polyreactivity of CLL BCRs correlates with inferior clinical outcome indicates that further stimulation of CLL via autoantigen (in addition to its self-binding) may modulate signaling outcome, and result in increased NF-kB activation, and thereby increase the proliferation capacity [52] . A recent study suggests that a subgroup of follicularlymphoma-derived BCRs bind themselves; however, whether this is via a similar mechanism -on a single-cell level -remains to be determined, as well as its clinical impact [45, 54] .
TREATMENT OPTIONS TARGETING THE B-CELL RECEPTOR SIGNALING PATHWAY
Despite clinical improvement, particularly indolent B-cell non-Hodgkin's lymphomas (B-NHL) lack persistent response rates to current therapies and remain mainly incurable. Given the importance of the BCR signaling pathway in many B-NHLs, drug discovery efforts have focused on the BCR pathway and several molecular targets have been evaluated in different clinical trials.
SYK inhibition
SYK is a key element of the BCR pathway [55] . The first clinically relevant SYK inhibitor fostamatinib (also called R406 or the oral form R788; AstraZeneca Pharmaceuticals, London, UK) is an ATP-competitive inhibitor that has been shown to inhibit BCR signaling in CLL and ABC-DLBCL models [56] [57] [58] . In a phase 1 study of patients with relapsed hematologic malignancies, fostamatinib induced objective response rates (ORRs) of 55% in CLL, 24% in DLBCL, 11% in MCL, and 10% in follicular lymphoma [59] . In this study, all patients with CLL experienced an increase in circulating lymphocytes following initial treatment, a phenomenon that has also been noted in patients treated with other BCR pathway inhibitors, which might be because of common signaling events after microenvironmental stimuli [55, 60] . However, in-vitro kinase assays demonstrated that fostamatinib can also inhibit kinases, that is FLT3, KIT, Lck, JAK1, and JAK3, with comparable potencies [61] . Other more specific SYK inhibitors such as GS-9973 (Gilead Sciences, Foster City, CA, USA) [62] and PRT062607 (Portola Pharmaceuticals, South San Francisco, CA, USA) are currently tested in clinical trials. In-vitro data shows antiproliferative activity against DLBCL cell lines and inhibition of the BCR signaling pathway [63, 64] .
Bruton's tyrosine kinase inhibition
Ibrutinib (PCI-32765) is an orally available, highly selective kinase inhibitor that irreversibly binds to the C481 residue of BTK and has low off-target effects. In February 2013, it was designated a 'breakthrough therapy' by the US FDA for the treatment of patients with relapsed or refractory MCL and Waldenström macroglobulinemia. A phase 1 study revealed safety and an ORR of 60% in relapsed or refractory, aggressive, and indolent lymphoma at escalating oral doses [65 && ,66] . In elderly, previously untreated CLL and small lymphocytic lymphoma patients, ibrutinib was found to be well tolerated and effective (71% ORR) in a phase 1b/2 trial [67] . Interestingly, similar to the SYK inhibitor [59] , most patients treated with ibrutinib experienced an initial lymphocytosis as a consequence of a lymphocyte egress from nodal compartments [68] , supposedly because of common signaling events from the microenvironment stimuli [69] . For indolent lymphoma, the results are reviewed in [70] . In aggressive lymphoma, ibrutinib revealed an ORR of 68% in MCL [71 & ] and showed substantial response rates in the relapsed, refractory ABC-DLBCL (ORR ¼ 40%). In contrast, the ORR for GCB DLBCL was only 5%, consistent with the concept that this subgroup is not dependent on BCR signaling [48] . In addition, combination of ibrutinib with either rituximab alone or both rituximab and bendamustine have revealed very promising initial ORRs (ibrutinib and rituximab 85%; ibrutinib and bendamustine and rituximab 92%) [72] [73] [74] .
For ibrutinib, mutation of the C481 BTK-binding site (BTK C481S ) within the tyrosine kinase domain was found in 4 of 13 patients with acquired resistance [75, 76] . However, only some of the clinically evident ibrutinib-resistant cases can be attributed to mutations in BTK or other genes of the BCR signaling pathway, such as CARD11 [48] . Further mutations in genes that confer resistance to necroptosis such as RIPK1 Q375 Ã or constitutive activation of KRAS via Q61H conferred resistance to ibrutinib in vitro [77] .
PI3K inhibition
The PI3K pathway is a promising therapeutic target as it is a downstream target of the BCR and the SYK kinase [78] . In addition, its negative regulator phosphatase and tensin homolog (PTEN) is frequently deleted or deregulated in B-NHL [79] . Initial in-vitro studies have indicated that different PI3K inhibitors were promising in CLL [80] , ABC-DLBCL [48, 81] , and MCL [82] . In addition, there is evidence that tonic BCR signaling mainly utilized the PI3K pathway, supporting a rationale for PI3K inhibition in Burkitt's lymphoma [13,37 & ,83] . Clinically tested PI3K inhibitors are idelalisib and IPI-145. Idelalisib (formally called GS-1101 or CAL-101) reversibly inhibits the PI3Kd isoform of the p110 catalytic subunit. A phase I trial in relapsed or refractory CLL revealed that idelalisib was well tolerated and reduced lymphadenopathy and phosphorylation of the downstream molecule protein kinase B. As described for fostamatinib and ibrutinib, idelalisib also caused an initial increase in lymphocyte count as a consequence of a regress from the protective microenvironment. A phase 2 study of idelalisib in heavily pretreated indolent lymphoma patients revealed a response rate of 57% [84, 85 && ]. IPI-145 (formerly INK-1147; Infinity Pharmaceuticals, Cambridge, MA, USA) is another selective PI3K inhibitor that targets both PI3K-d and PI3K-g isoforms, and has been evaluated in CLL [86] . The PI3K-g isoform has additional functions in mediating mast cell activation and chemokineinduced cell trafficking [87, 88] .
MALT1 inhibition
A compound screen for the ability to inhibit the cleavage function of a dimeric, active form of MALT1 resulted in identification of novel MALT1 inhibitors. These molecules decreased NF-kB signaling, reduced target gene expression and induced apoptosis at low concentrations in ABC-DLBCL but not GC-like DLBCL in vitro and in vivo [89, 90] . As some of the used components have already been used in the clinical setting for neurological symptoms, they might be useful for the treatment of ABC-DLBCL and other MALT1-dependent lymphomas in the near future.
CONCLUSION
In summary, the recent studies identified tyrosine kinases (SYK and BTK), PI3K, and MALT1 within the BCR pathway as a novel class of therapeutic targets in B-cell lymphomas. Although the BCR pathway is integrated in oncogenic signaling in the majority of mature B-cell lymphomas, this is only the case for a small fraction of B-cell lineage ALL. Future studies will elucidate the mechanistic basis of divergent outcomes of BCR signaling in B-cell malignancies.
